Effects of steroid hormones on the secretion of hemostatic factors in, and angiogenic properties of, human vascular endothelial cells

Gynecological Endocrinology

Volumn 10, Issue SUPPL. 2, 1996, Pages 105-110

  Kooistra, T ^a   Lansink, M ^a   Van Kesteren, P ^b   Koolwijk, P ^a   Toet, K ^a   Peters, E ^a   Hegeman, R ^a   Emeis, J ^a   Stehouwer, C ^b   Gooren, L ^b   Van Hinsbergh, V W M ^a  

^a TNO   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Angiogenesis; Human endothelial cells; Plasminogen activators; Steroid hormones; Von Willebrand factor

Indexed keywords

EID: 2642649669     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.3109/09513599609045640     Document Type: Article

References (32)

1. Colditz, G.A., Willett, W.C., Stampfer, M.J., Rosner, B., Speizer, F.E. and Hennekens, C.H. (1987). Menopause and the risk of coronary heart disease in women. N. Engl. J. Med., 316, 1105-10
2. Bush, T.L., Barrett-Connor, E., Cowan, L.D., Criqui, M.H., Wallace, R.B., Suchindran, C.M., Tyroler, H.A. and Rifkind, B.M. (1987). Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation, 75, 1102-9
3. Sullivan, J.M., Van der Zwaag, R., Lemp, G.F., Hughes, J.P., Maddock, V., Kroetz, F.W., Ramanathan, K.B. and Mirvis, D.M. (1988). Postmenopausal estrogen use and coronary atherosclerosis. Ann. Intern. Med., 108, 358-63
4. Stampfer, M.J., Colditz, G.A., Willett, W.C., Manson, J.E., Rosner, B., Speizer, F.E. and Hennekens, C.H. (1991). Postmenopausal estrogen therapy and cardiovascular disease. N. Engl. J. Med., 325, 756-62
5. Kuhn, F.E. and Rackley, C.E. (1993). Coronary artery disease in women: risk factors, evaluation, treatment, and prevention. Arch. Intern. Med., 143, 2626-36
6. Knopp, R.H. (1988). The effects of postmenopausal estrogen therapy on the incidence of arteriosclerotic vascular disease. Obstet. Gynecol., 72, 23S-30S
7. Writing group for PEPI trial (1995). Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. J. Am. Med. Assoc., 273, 199-208
8. Barrett-Connor, E. and Bush, T.L. (1991). Estrogen and coronary heart disease in women. J. Am. Med. Assoc., 265, 1861-7
9. Collins, P., Rosano, G.M.C., Jiang, C., Lindsay, D., Sarrel, P.M. and Poole-Wilson, P.A. (1993). Hypothesis: cardiovascular protection by oestrogen: a calcium antagonist effect? Lancet, 341, 1264-5
10. Hayashi, T., Fukuto, J.M., Ignarro, L.J. and Chaudhuri, G. (1992). Basal release of nitric oxide from aortic rings is greater in female rabbits than in male rabbits: implications for atherosclerosis. Proc. Natl. Acad. Sci. USA, 89, 11259-63
11. Van Buren, G., Yang, D. and Clark, K.E. (1992). Estrogen-induced uterine vasodilatation is antagonized by L-nitroarginine methyl ester, an inhibitor of nitric oxide synthesis. Am. J. Obstet. Gynecol., 16, 828-33
12. Polderman, K.H., Stehouwer, C.D.A., Van Kamp, G.J., Dekker, G.A., Verbeugt, F.W.A. and Gooren, L.J.G. (1993). Influence of sex hormones on plasma endothelin levels. Ann. Intern. Med., 118, 429-32
13. Mikkola, T., Turunen, P., Avela, K., Orpana, A., Viinikka, L. and Ylikorkala, O. (1995). 17β-estradiol stimulates prostacyclin, but not endothelin-1, production in human vascular endothelial cells. J. Clin. Endocrinol. Metab., 80, 1832-6
14. Van den Eijnden-Schrauwen, Y., Kooistra, T., De Vries, R.E.M. and Emeis, J.J. (1995). Studies on the acute release of tissue-type plasminogen activator from human endothelial cells in vitro and in rats in vivo : evidence for a dynamic storage pool. Blood, 85, 3510-17
15. Sinha, S. and Wagner, D.D. (1987). Intact microtubules are necessary for complete processing, storage and regulated secretion of von Willebrand factor by endothelial cells. Cell Biol., 43, 377-83
16. D'Amato, R.J., Lin, C.M., Flynn, E., Folkman, J. and Hamel, E. (1994). 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc. Natl. Acad. Sci. USA, 91, 3964-8
17. Fotsis, T., Zhang, Y., Pepper, M.S., Adlercreutz, H., Montesano, R., Nawroth, P.P. and Schweigerer, L. (1994). The endogenous oestrogen metabolite 2-methoxyestradiol inhibits angiogenesis and suppresses tumour growth. Nature, 368, 237-9
18. Morales, D.E., McGowan, K.A., Grant, D.S., Maheshwari, S., Bhartiya, D., Cid, M.C., Kleinman, H.K. and Schnaper, H.W. (1995). Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in murine model. Circulation, 91, 755-63
19. Koolwijk, P., Van Erck, M.G.M., De Vree, W.J.A., Vermeer, M.A., Weich, H.A., Hanemaaijer, R. and Van Hinsbergh, V.W.M. (1996). Cooperative effect of tumor necrosis factor α and angiogenic growth factors on the formation of tubular structures of human microvascular endothelial cells in a three-dimensional fibrin matrix. Role of pericellular urokinase activity. J. Cell. Biol., 132, 1177-88
20. Siegbahn, A. and Ruusuvaara, L. (1988). Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers. Thromb. Haemostas., 60, 361-4
21. Gevers Leuven, J.A., Kluft, C., Bertina, R.M. and Hessel, L.W. (1987). Effects of two low-dose oral contraceptives on circulating components of the coagulation and fibrinolytic systems. J. Lab. Clin. Med., 109, 631-6
22. Anderson, R.A., Ludlam C.A. and Wu, F.C.W. (1995). Haemostatic effects of supraphysiological levels of testosterone in normal men. Thromb. Haemostas., 74, 693-7
23. Caron, P., Bennet, A., Camare, R., Louvet, J.P., Boneu, B. and Sié, P. (1989). Plasminogen activator inhibitor in plasma is related to testosterone in men. Metabolism, 38, 1010-5
24. Kooistra, T., Bosnia, P.J., Jespersen, J. and Kluft, C. (1990). Studies on the mechanism of action of oral contraceptives with regard to fibrinolytic variables. Am. J. Obstet. Gynecol., 163, 404-12
25. Cho, H. and Katzenellenbogen, B.S. (1993). Synergistic activation of estrogen receptor-mediated transcription by estradiol and protein kinase activators. Mol. Endocrinol., 7, 441-52
26. 2-macroglobulin receptor mediates cellular uptake of pro-urokinase. J. Biol. Chem., 268, 21862-7
27. Narita, M., Bu, G., Herz, J. and Schwartz, A. (1995). Two receptor systems are involved in the plasma clearance of tissue-type plasminogen activator (t-PA) in vivo. J. Clin. Invest., 96, 1164-8
28. Harrison, R.L. and McKee, P.A. (1984). Estrogen stimulates von Willebrand Factor production by cultured endothelial cells. Blood, 63, 657-65
29. Kooistra, T., Van den Berg, J., Töns, A., Platenburg, G., Rijken, D.C. and Van den Berg, E. (1987). Butyrate stimulates tissue-type plasminogen-activator synthesis in cultured human endothelial cells. Biochem. J. 247, 605-12
30. Chester, A.H., Jiang, C., Borland, J.A., Yacoub, M.H. and Collins, P. (1995). Oestrogen relaxes human epicardial coronary arteries through non-endothelium-dependent mechanisms. Coron. Art. Dis., 6, 417-22
31. Pepper, M.S., Vassalli, J.-D., Wilks, J.W., Schweigerer, L., Orci, L. and Montesano, R. (1994). Modulation of bovine microvascular endothelial cell proteolytic properties by inhibitors of angiogenesis. J. Cell. Biochem., 55, 419-34
32. Battegay, E.J. (1995). Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J. Mol. Med., 73, 333-46